Trial · NCT00553696
Results by group62
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 62
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With First Cycle Dose-limiting Toxicities (DLTs) | Sunitinib 25 mg CDD + S-1 + Cisplatin | 2 | participants | ||
| Number of Participants With First Cycle Dose-limiting Toxicities (DLTs) | Sunitinib 25 mg 2/2 + S-1 + Cisplatin (Dose Escalation Cohort) | 1 | participants | ||
| Number of Participants With First Cycle Dose-limiting Toxicities (DLTs) | Sunitinib 37.5 mg 2/2 + S-1 + Cisplatin | 3 | participants | ||
| Maximum Observed Plasma Concentration (Cmax) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662) | Sunitinib 25 mg 2/2 + Cisplatin + S-1 (MTD Expansion Cohort) | Cycle 1 Day 1: Sunitinib (Sunitinib Alone) | 14.47 | Standard Deviation 5.3414 | nanogram per milliliter (ng/mL) |
| Maximum Observed Plasma Concentration (Cmax) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662) | Sunitinib 25 mg 2/2 + Cisplatin + S-1 (MTD Expansion Cohort) | Cycle 2 Day 1:Sunitinib (Sunitinib+S-1+Cisplatin) | 13.14 | Standard Deviation 3.1675 | nanogram per milliliter (ng/mL) |
| Maximum Observed Plasma Concentration (Cmax) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662) | Sunitinib 25 mg 2/2 + Cisplatin + S-1 (MTD Expansion Cohort) | Cycle 1 Day 1: SU-012662 (Sunitinib Alone) | 2.487 | Standard Deviation 1.1515 | nanogram per milliliter (ng/mL) |
| Maximum Observed Plasma Concentration (Cmax) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662) | Sunitinib 25 mg 2/2 + Cisplatin + S-1 (MTD Expansion Cohort) | Cycle 2 Day 1:SU-012662(Sunitinib+S-1+Cisplatin) | 2.331 | Standard Deviation 1.2943 | nanogram per milliliter (ng/mL) |
| Maximum Observed Plasma Concentration (Cmax) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662) | Sunitinib 25 mg 2/2 + Cisplatin + S-1 (MTD Expansion Cohort) | Cycle1 Day 1:Total Drug (Sunitinib Alone) | 16.86 | Standard Deviation 6.3194 | nanogram per milliliter (ng/mL) |
| Maximum Observed Plasma Concentration (Cmax) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662) | Sunitinib 25 mg 2/2 + Cisplatin + S-1 (MTD Expansion Cohort) | Cycle 2 Day 1:Total Drug(Sunitinib+S-1+Cisplatin) | 15.41 | Standard Deviation 3.7667 | nanogram per milliliter (ng/mL) |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662) | Sunitinib 25 mg 2/2 + Cisplatin + S-1 (MTD Expansion Cohort) | Cycle 1 Day 1: Sunitinib ( Sunitinib Alone) | 5.97 | Full Range 3.83 to 8.00 | hrs |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662) | Sunitinib 25 mg 2/2 + Cisplatin + S-1 (MTD Expansion Cohort) | Cycle 2 Day 1: Sunitinib (Sunitinib+S-1+Cisplatin) | 7.97 | Full Range 3.97 to 9.93 | hrs |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662) | Sunitinib 25 mg 2/2 + Cisplatin + S-1 (MTD Expansion Cohort) | Cycle 1 Day 1: SU-012662 ( Sunitinib Alone) | 8.00 | Full Range 3.83 to 10.1 | hrs |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662) | Sunitinib 25 mg 2/2 + Cisplatin + S-1 (MTD Expansion Cohort) | Cycle 2 Day 1: SU-012662 (Sunitinib+S-1+Cisplatin) | 9.25 | Full Range 5.97 to 23.8 | hrs |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662) | Sunitinib 25 mg 2/2 + Cisplatin + S-1 (MTD Expansion Cohort) | Cycle1 Day1:Total Drug ( Sunitinib Alone) | 5.97 | Full Range 3.83 to 9.22 | hrs |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662) | Sunitinib 25 mg 2/2 + Cisplatin + S-1 (MTD Expansion Cohort) | Cycle 2 Day 1:Total Drug (Sunitinib+S-1+Cisplatin) | 7.92 | Full Range 3.97 to 9.25 | hrs |
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662) | Sunitinib 25 mg 2/2 + Cisplatin + S-1 (MTD Expansion Cohort) | Cycle 1 Day 1: Sunitinib (Sunitinib Alone) | 214.6 | Standard Deviation 61.682 | ng*h/mL |
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662) | Sunitinib 25 mg 2/2 + Cisplatin + S-1 (MTD Expansion Cohort) | Cycle 2 Day 1: Sunitinib (Sunitinib+S-1+Cisplatin) | 211.9 | Standard Deviation 46.092 | ng*h/mL |
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662) | Sunitinib 25 mg 2/2 + Cisplatin + S-1 (MTD Expansion Cohort) | Cycle 1 Day 1: SU-012662 (Sunitinib Alone) | 39.77 | Standard Deviation 12.857 | ng*h/mL |
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662) | Sunitinib 25 mg 2/2 + Cisplatin + S-1 (MTD Expansion Cohort) | Cycle 2 Day 1: SU-012662 (Sunitinib+S-1+Cisplatin) | 44.83 | Standard Deviation 24.046 | ng*h/mL |
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662) | Sunitinib 25 mg 2/2 + Cisplatin + S-1 (MTD Expansion Cohort) | Cycle 1 Day 1: Total Drug (Sunitinib Alone) | 254.4 | Standard Deviation 70.913 | ng*h/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00553696/results